Literature DB >> 31656762

The dark side of immunotherapy: challenges facing the new hope in cancer treatment.

Eduard Teixidor1, Joaquim Bosch-Barrera1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31656762      PMCID： PMC6789311          DOI： 10.21037/atm.2019.07.69

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

Review 1.  Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.

Authors:  Sheng Zhang; Fei Liang; Wenfeng Li; Qing Wang
Journal:  Eur J Cancer       Date:  2017-07-15       Impact factor: 9.162

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Hyperprogressive disease: a distinct effect of immunotherapy?

Authors:  Vinita Popat; David E Gerber
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

4.  Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.

Authors:  Tomohiro F Nishijima; Shlomit S Shachar; Hyman B Muss; Kazuo Tamura
Journal:  Oncologist       Date:  2018-12-14

5.  Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.

Authors:  Yan Tie; Xuelei Ma; Chenjing Zhu; Ye Mao; Kai Shen; Xiawei Wei; Yan Chen; Heng Zheng
Journal:  Int J Cancer       Date:  2016-11-16       Impact factor: 7.396

6.  Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.

Authors:  Yukihiro Toi; Shunichi Sugawara; Yosuke Kawashima; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Kyoji Tsurumi; Kana Suzuki; Hisashi Shimizu; Jun Sugisaka; Hirotaka Ono; Yutaka Domeki; Keisuke Terayama; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda
Journal:  Oncologist       Date:  2018-06-22

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events.

Authors:  Bin Zhao; Hong Zhao; Jiaxin Zhao
Journal:  J Immunother Cancer       Date:  2018-10-03       Impact factor: 13.751

9.  Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Authors:  Eduard Teixidor; Elia Sais; Carmen Amalia Vásquez; Walter Carbajal; Alejandro Hernández; Gloria Sánchez; Angel Izquierdo; Sara Verdura; Javier A Menéndez; Joaquim Bosch-Barrera
Journal:  Oncotarget       Date:  2018-08-31

Review 10.  Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.

Authors:  Xiaolei Li; Changshun Shao; Yufang Shi; Weidong Han
Journal:  J Hematol Oncol       Date:  2018-02-27       Impact factor: 17.388
View more
  2 in total

Review 1.  Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review).

Authors:  Silvia Vivarelli; Luca Falzone; Giulia Costanza Leonardi; Mario Salmeri; Massimo Libra
Journal:  Int J Oncol       Date:  2021-08-13       Impact factor: 5.650

Review 2.  Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment.

Authors:  Reem Altaf; Sarmad Sheraz Jadoon; Syed Aun Muhammad; Umair Ilyas; Yongtao Duan
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.